Scilex licenses Datavault’s AI technology

Scilex (SCLX) has in-licensed a worldwide exclusive license, with right to sublicense, to Datavault (DVLT) AI’s proprietary AI-driven technology for the use within the biotech and biopharma industry, specifically enabling the creation and operation of a Biotech Exchange platform. This license allows Scilex to leverage Datavault AI’s advanced data platforms for secure tokenization, trading, and monetization of biotech assets, including genomic, DNA data, diagnostic, therapeutic products, genetic and drug information. Scilex also believes that this advanced data platform will have the potential to expand into the creation of a Pharmaceutical Exchange platform which will potentially revolutionize the entire pharmaceutical industry. Scilex believes that there is an opportunity to tokenize approximately $2.0T dollars pharmaceutical drug sales and diagnostic sales. The license centers on Datavault AI’s portfolio of intellectual property. This technology is supported by a suite of issued and pending patents that collectively enable the Biotech Exchange. According to the licensing agreement, Scilex shall pay a non-refundable upfront license fee in four equal installments of $2.5M each on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Datavault will earn sales milestone payments of up to an aggregate of $2.55B illion upon the achievement of certain applicable sales milestones.